Browse all past biotechnology intelligence, clinical developments, and industry updates.
Innovent Biologics is expanding its global Phase 3 MarsLight-11 study of IBI363/TAK-928, an alpha-biased IL-2/PD-1 bispecific fusion protein, in immunotherapy-resistant NSCLC to include patients with non-squamous NSCLC.
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of an IPO window that has produced 27 newly public biotechs so far this year, with ADARx raising $446 million.
Manufacturers are redesigning their processes to balance both better future emergency vaccine mobilization and the more demanding work of maintaining flexible, commercially viable manufacturing networks.
A U.K. watchdog has scolded Eli Lilly over a press release, arguing that “promotional and emotive” language brought discredit on the pharma industry.
Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
Ahead of its upcoming merger with Supernus Pharmaceuticals, Indivior is returning its PAM drug program to partner Addex Therapeutics.
Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
The FDA signed off on Eli Lilly's Onswik, also known as insulin efsitora alfa-gobe, as a once-weekly basal insulin for adults with type 2 diabetes, setting up a direct U.S. competitor to Novo's Awiqli.
Lundbeck plans to relocate its U.S. headquarters from Deerfield, Illinois to Greater Boston, where the Danish neuroscience drugmaker will establish a global innovation hub and expand its artificial intelligence work.
The FDA approved Merck's HIF-2 alpha inhibitor Welireg in combination with Eisai-partnered Lenvima for second-line clear cell renal cell carcinoma following a PD-(L)1 inhibitor, lifting the drug beyond its original third-line use.
Rare disease pharma Mirum scored an approval for its ultra-rare bone lesion treatment it bought from Incyte.
Mylan asks US court to clear Wegovy generic from Novo patent claims
A jury awarded Nektar Therapeutics $90 million in damages after siding with the biotech, which accused Eli Lilly of botching an analysis of their formerly partnered autoimmune drug.